The Centor transaction is part of a combined approximately EUR 1.5 billion sale agreed with Apax Funds, while closing of the Primary Packaging Plastics business remains expected in the first half of 2027. IN BRIEFKEY TAKEAWAYSFAQs Gerresheimer has completed the … Read the full press release
Posted in Business, Financial, Germany, Industrial, Pharma & Biotech
Tagged Achim Schalk, Apax Funds, Apax Partners LLP, Centor, Centor US Holding Inc., corporate refinancing, debt reduction, drug delivery systems, Duesseldorf, Germany, Gerresheimer, Gerresheimer advances portfolio restructuring with completion of Centor transaction, Gerresheimer AG, Gerresheimer completes Centor sale as part of approximately EUR 1.5 billion portfolio transaction, Gerresheimer completes U.S. Centor sale and plans further debt reduction, Gerresheimer finalises Centor disposal and moves forward with Primary Packaging Plastics carve-out, portfolio restructuring, PPP business, primary packaging, Primary Packaging Plastics, United States, Wolf Lehmann
(IN BRIEF) SCHOTT Pharma has reaffirmed its commitment to science-based climate action after the Science Based Targets initiative (SBTi) validated the updated climate targets of the SCHOTT Group, including SCHOTT Pharma’s business scope. The updated framework keeps the Group’s target … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Germany, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 1.5°C pathway, 2019 baseline, 27.5 percent Scope 3 reduction, 46.2 percent emissions reduction, Alliance to Zero, Carl Zeiss Foundation, circular economy, Climate Action, climate neutral by 2030, decarbonisation, drug delivery systems, Energize, energy attribute certificates, energy efficiency, EUR 986 million revenue, fiscal year 2030, Frankfurt Stock Exchange, Germany, GHG emissions, glass tubing, greenhouse gas emissions, healthcare value chain, heat recovery, injectable drugs, Lea Kaiser, low-emission melting technologies, Mainz, membrane-based system, natural gas reduction, Paris Agreement, pharmaceutical containment solutions, pharmaceutical quality, product carbon footprint, regulatory requirements, Reinhard Mayer, renewable electricity sourcing, renewable energy, SBTi, SCHOTT Group, SCHOTT Pharma, SCHOTT Pharma Reaffirms Science-Based Climate Action Following SBTi Validation, SCHOTT Pharma Shifts Climate Strategy Toward Measurable Scope 3 Emissions Reductions, SCHOTT Pharma Targets Value Chain Emissions With Updated Science-Based Climate Framework, Science Based Targets initiative, science-based targets, Scope 1 emissions, scope 2 emissions, Scope 3 emissions, secondary packaging, supplier decarbonisation, Switzerland, technological innovation, updated climate targets, value chain emissions, water efficiency, Water for Injection, WFI
(IN BRIEF) SCHOTT Pharma delivered a resilient performance during the first half of fiscal year 2026, reporting revenue growth despite ongoing market challenges and maintaining strong profitability. The company benefited from continued demand for high-value pharmaceutical containment products, especially sterile … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology
Tagged biologics, cartriQ BioPure, Christian Mias, drug containment solutions, drug delivery systems, EBITDA, Frankfurt Stock Exchange, Free cash flow, Germany, GLP-1 therapies, Healthcare Innovation, high-value solutions, Hungary, HVS, injectable drugs, Mainz, mRNA Vaccines, pharmaceutical manufacturing, pharmaceutical packaging, polymer syringes, prefillable glass syringes, Reinhard Mayer, SCHOTT Pharma, SCHOTT Pharma Confirms 2026 Outlook Following Resilient First-Half Results and Expansion Investments, SCHOTT Pharma Maintains Stable Growth and Doubles Free Cash Flow in First Half of Fiscal 2026, SCHOTT Pharma Strengthens Financial Position as Demand for High-Value Drug Solutions Continues to Rise, SDAX, specialty vials, sterile cartridges, Switzerland
(IN BRIEF) SCHOTT Pharma has introduced cartriQ® BioPure, a high-performance sterile glass cartridge developed to meet the needs of modern biologic therapies. Designed with enhanced chemical resistance and improved extractables and leachables control, the cartridge supports long-term stability for sensitive … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged autoinjectors, biologics packaging, biotech medicines, cartriQ BioPure, CPHI Milan 2026, drug delivery systems, drug stability, EVERIC pure vials, extractables and leachables, FIOLAX Pro glass, fusion proteins, monoclonal antibodies, pharmaceutical packaging, SCHOTT Pharma, SCHOTT Pharma expands biologics packaging portfolio with advanced cartriQ BioPure glass cartridge for improved drug stability, SCHOTT Pharma introduces cartriQ BioPure to expand advanced packaging solutions for sensitive biologics, sterile glass cartridge, syriQ BioPure syringes
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?